pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)
Shanghai Antengene Corporation
Shanghai Antengene Corporation Limited
Shanghai Antengene Corporation is a pharma organization headquartered in SAINT-LAURENT, CN. Primary therapeutic focus areas include Relapsed/Refractory Diffuse Large B-cell Lymphoma, Non-muscle invasive bladder cancer (N
SAINT-LAURENT, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- SAINT-LAURENT, CN
- Programs
- 3
- Drugs
- 8
- Patents
- 53
ATG-010 and ATG-008
Phase 1 · other · Relapsed/Refractory Diffuse Large B-cell Lymphoma
ATG-010 and ATG-008 for Relapsed/Refractory Diffuse Large B-cell Lymphoma is a Phase 1 program (other) at Shanghai Antengene Corporation Limited with 1 ClinicalTrials.gov record(s).
Internal code ATG-008&010-DLBCL-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Antengene Corporation Limited
- Phase
- Phase 1
- Modality
- other
- Indication
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- terminated
- Trials
- 1